D
15.43
-0.02 (-0.13%)
| Previous Close | 15.45 |
| Open | 15.43 |
| Volume | 1,915,947 |
| Avg. Volume (3M) | 1,694,730 |
| Market Cap | 2,256,051,200 |
| Price / Sales | 3.64 |
| Price / Book | 2.17 |
| 52 Weeks Range | |
| Earnings Date | 5 Nov 2025 |
| Diluted EPS (TTM) | -2.64 |
| Total Debt/Equity (MRQ) | 4.59% |
| Current Ratio (MRQ) | 9.56 |
| Operating Cash Flow (TTM) | -365.54 M |
| Levered Free Cash Flow (TTM) | -257.54 M |
| Return on Assets (TTM) | -22.58% |
| Return on Equity (TTM) | -35.21% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Bearish |
| Biotechnology (Global) | Mixed | Bearish | |
| Stock | Denali Therapeutics Inc. | Bullish | Bearish |
AIStockmoo Score
0.4
| Analyst Consensus | 1.5 |
| Insider Activity | NA |
| Price Volatility | -2.0 |
| Technical Moving Averages | 0.0 |
| Technical Oscillators | 2.0 |
| Average | 0.38 |
|
Denali Therapeutics Inc is a biotechnology company that is engaged in developing and discovering therapeutics to defeat neurodegeneration disease. The company's development programs include the LRRK2 Inhibitor Program, which develops brain penetrant small molecule LRRK2 inhibitor product candidates for Parkinson's disease. Its key products include DNL201, DNL151, DNL747, ATV (Antibody Transport Vehicle), ETV (Enzyme Transport Vehicle), and others. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Growth |
| % Held by Insiders | 9.86% |
| % Held by Institutions | 94.15% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Crestline Management, Lp | 30 Jun 2025 | 3,860,732 |
| 52 Weeks Range | ||
| Median | 30.00 (94.43%) | |
| Total | 1 Buy | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Morgan Stanley | 18 Aug 2025 | 30.00 (94.43%) | Buy | 14.82 |
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 11 Aug 2025 | Announcement | Denali Therapeutics Reports Second Quarter 2025 Financial Results and Business Highlights |
| 07 Jul 2025 | Announcement | Denali Therapeutics Announces FDA Acceptance and Priority Review of Biologics License Application (BLA) for Tividenofusp Alfa for Hunter Syndrome (MPS II) |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |